Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Preferred stock Series X redeemable convertible preferred stock	Common stock	Additional paid-in capital	Accumulated deficit	Accumulated other comprehensive loss	Total
Beginning balance at Dec. 31, 2021	$ 96,398	$ 13	$ 481,709	$ (455,809)	$ 0	$ 122,311
Beginning balance (in shares) at Dec. 31, 2021	31,455	13,016,955
Increase (Decrease) in Shareholders' Equity
Expense related to warrants inherited in acquisition of Quellis			1,542			1,542
Stock-based compensation expense			1,209			1,209
Unrealized loss on short-term investments					(53)	(53)
Net loss				(15,323)		(15,323)
Ending balance at Mar. 31, 2022	$ 96,398	$ 13	484,460	(471,132)	(53)	109,686
Ending balance (in shares) at Mar. 31, 2022	31,455	13,016,955
Beginning balance at Dec. 31, 2022	$ 96,398	$ 28	632,512	(507,643)	(79)	221,216
Beginning balance (in shares) at Dec. 31, 2022	31,455	27,501,340
Increase (Decrease) in Shareholders' Equity
Issuance of common stock upon the conversion of preferred stock	(348)	57,910
Issuance of common stock upon the conversion of preferred stock	$ (1,074)		1,074
Issuance of common stock upon exercise of options			37			37
Issuance of common stock upon exercise of options (in shares)		427,468
Stock-based compensation expense			1,220			1,220
Unrealized loss on short-term investments					75	75
Net loss				(11,188)		(11,188)
Ending balance at Mar. 31, 2023	$ 95,324	$ 28	$ 634,843	$ (518,831)	$ (4)	$ 211,360
Ending balance (in shares) at Mar. 31, 2023	31,107	27,986,718